详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Nedaplatin plus Docetaxel versus Cisplatin plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

单位： [1]Shanghai Jiao Tong Univ, Shanghai Lung Tumor Clin Med Ctr, Shanghai Chest Hosp, Shanghai, Peoples R China [2]Cent S Univ, Dept Resp Med, Xiangya Hosp, Changsha, Hunan, Peoples R China [3]Fourth Mil Univ, Dept Resp, Xijing Hosp, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China [4]Huazhong Univ Sci & Technol, Dept Oncol, Tongji Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China [5]Nanjing Mil Gen Hosp, Dept Resp Med, Nanjing, Jiangsu, Peoples R China [6]Zhejiang Univ, Dept Chest Tumor, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China [7]Zhejiang Canc Hosp, Oncol, Hangzhou, Zhejiang, Peoples R China [8]Hust, Tumor Ctr, Wuhan Union Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China [9]Zhengzhou Univ, Dept Chest Tumor, Henan Canc Hosp, Zhengzhou, Henan, Peoples R China [10]Beijing Univ, Dept Chest Tumor, Beijing Canc Hosp, Beijing, Peoples R China [11]Guangxi Canc Hosp, Dept Chest Tumor, Nanning, Peoples R China [12]Capital Med Univ, Dept Chest Tumor, Beijing Chest Hosp, Beijing, Peoples R China

出处：

DOI：

ISSN：

关键词： Nedaplatin Squamous cell lung carcinoma randomized trial

语种：

WOS：

中科院(CAS)分区：

出版当年[2016]版：

大类 | 2 区医学

小类 | 2 区肿瘤学 2 区呼吸系统

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

JCR分区：

出版当年[2015]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

最新[2023]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 21.1 最新[2023版] 16.5 最新五年平均 5.04 出版当年[2015版] 4.932 出版当年五年平均 5.282 出版前一年[2014版] 6.595 出版后一年[2016版]

第一作者：

第一作者单位： [1]Shanghai Jiao Tong Univ, Shanghai Lung Tumor Clin Med Ctr, Shanghai Chest Hosp, Shanghai, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung - A Multicenter, Open-label, Randomized, Phase III Trial [2]Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3) [3]Adenocarcinoma transformed into squamous cell carcinoma in non-small cell lung cancer [4]Integrated analyses of copy number variations and gene differential expression in lung squamous-cell carcinoma [5]Identification and assessment of PLK1/2/3/4 in lung adenocarcinoma and lung squamous cell carcinoma: Evidence from methylation profile [6]Distinct Roles of VEGFA and ANGPT2 in Lung Adenocarcinoma and Squamous Cell Carcinoma [7]Differential expression of bone morphogenetic protein 5 in human lung squamous cell carcinoma and adenocarcinoma [8]Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial [9]Multiline treatment of advanced squamous cell carcinoma of the lung: A case report and review of the literature [10]Identification of crucial regulatory relationships between long non-coding RNAs and protein-coding genes in lung squamous cell carcinoma